Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03256253 · ClinicalTrials.gov registry record · Phase 2
Pregabalin as Treatment for Alcohol Use Disorder
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT03256253 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 18 participants.
The verdict
NCT03256253, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The proposed protocol is an 8 week open label outpatient pilot trial of the safety and efficacy of pregabalin (Lyrica) in the treatment of alcohol use disorder. The primary objective of the study is to determine the efficacy of pregabalin in promoting alcohol abstinence among individuals with an alcohol use disorder.
Interventions
- DRUG Pregabalin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-02-15 |
| Est. Completion | 2020-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03256253
The ClinicalTrials.gov registry entry for NCT03256253 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pregabalin is the first listed.
NCT03256253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03256253 about?
NCT03256253 is a clinical study titled "Pregabalin as Treatment for Alcohol Use Disorder". The proposed protocol is an 8 week open label outpatient pilot trial of the safety and efficacy of pregabalin (Lyrica) in the treatment of alcohol use disorder. The primary objective of the study is to determine the efficacy of pregabalin in promoting alcohol abstinence among individuals with an alc...
What is the current status of trial NCT03256253?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2018-02-15. Estimated completion is 2020-05-31.
What interventions are being tested in trial NCT03256253?
The interventions under investigation include: Pregabalin (DRUG).
Who is sponsoring clinical trial NCT03256253?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.